TABLE 1.
Strains used in this study
| Strain or genotypea | Reference name | Phenotype (gene) | Source |
|---|---|---|---|
| D39 | D39 | Serotype 2 wild-type S. pneumoniae strain | 48 |
| M1T1 | 941079 | M type 1 wild-type strain with low capsule expression | 49 |
| M1 | SF370 | M type 1 wild-type strain | 50 |
| Δemm1 | SF370 △emm1 | M1 protein (emm1) deletion mutant in SF370 | 50 |
| M5 | Manfredo | M type 5 wild-type strain | 51 |
| Δemm5 | Manfredo △emm5 | M5 protein (emm5) deletion mutant in Manfredo | 51 |
| M6 | JRS4 | M type 6 wild-type strain from June Scott | 52 |
| M6ΔhasA | JRS46 | Capsule-deficient (hasA) mutant in JRS4 | June R. Scott |
| M11 | GAS-53 | Erythromycin-resistant clinical isolate expressing an ermB methylase | 53 |
| M12 | GAS-6 | Erythromycin-resistant clinical isolate expressing a mefA + msrD efflux pump | 53 |
| M18 | 87-282 | M type 18 wild-type strain with high capsule expression | 54 |
| M22 | GAS-8 | Erythromycin-resistant clinical isolate expressing a mefA + msrD efflux pump. This strain lacks the hasABC genes encoding hyaluronic acid capsule. | 53, 55 |
| M73 | GAS-138 | Erythromycin-resistant clinical isolate expressing a mefA + msrD efflux pump | 53 |
| M77 | GAS-125 | Erythromycin-resistant clinical isolate expressing an ermTR methylase | 53 |
| M89 | GAS-128 | Erythromycin-resistant clinical isolate expressing an ermB methylase | 53 |
| M3 strains | |||
| AM3 (H) | AM3 (H) | M type 3 strain with high capsule expression | 56 |
| SS-90 (H) | SS-90 | M type 3 strain with high capsule expression | 57 |
| SS-1271 (M) | SS-1271 | M type 3 strain with medium capsule expression | 58 |
| 94421 (M) | 94421 | M type 3 strain with medium capsule expression | 57 |
| 950802 (L) | 950802 | M type 3 strain with low capsule expression | 57 |
| 87-136 (L) | 87-136 | M type 3 strain with low capsule expression | 57 |
| M3 (M) | 950771 (GAS-771) | M type 3 wild-type strain, medium encapsulated, from child with necrotizing fasciitis and sepsis | 59 |
| Δemm3 | 355 | M type 3 (emm3) deletion mutant derived from 950771 | 59 |
| M3ΔhasA | 188 | Nonencapsulated isogen of 950771 with a Km insertion in hasA | 59 |
| Δslo | 500 | Streptolysin O (slo) deletion mutant derived from 950771 | 60 |
| Δslo ΔhasA | 781 | Nonencapsulated (deletion) and SLO-deficient (Km insertion) double mutant derived from 950771 | 19 |
| Δnga | C3 | NADase (nga) mutant of 950771 | 60 |
| Δslo Δnga | C42 | 950771 with deletion of SLO (slo) and NADase (nga) | 60 |
| ΔspeB | 241 | Cysteine protease (speB)-deficient mutant derived from 950771, Km insertion in speB | 59 |
| ΔsagA | 775 | 950771 with deletion of 60 bp in SLS (sagA) | 61 |
a
Capsule amount scale: 0 to 2 fg/CFU, low (L); 2.1 to 25 fg/CFU, medium (M); 26 to 90 fg/CFU, high (H).